The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

The weight-loss rivals provided positive updates on their obesity treatments but to differing reactions among investors.

Eli Lilly is far from a one-trick pony.

Eli Lilly (LLY 1.87%) just delivered another fantastic quarter, showcasing its impressive growth prospects. The company has ...

Eli Lilly shares hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug ...